Information Provided By: 
Fly News Breaks for July 7, 2015
VSAR
Jul 7, 2015 | 07:38 EDT
Canaccord raised Versartis' price target to $28 following the FDA removal of the partial clinical hold of VRS-317 trial. The firm expects positive interim six-month height velocity data by year-end 2016 and now expects a 70% chance of FDA approval vs. 50% previously. Shares are Buy rated.
News For VSAR From the Last 2 Days
There are no results for your query VSAR
